The Biotechnology and Medical Devices industries saw venture capitalists invest a total of $1.5 billion in the first quarter of 2012. While Medical Device venture funding accelerated, it could not offset the slowdown in Biotechnology and the first quarter of 2012 decreased 22% from the fourth quarter of 2011. Deal volume was also down from the previous quarter, dropping 11% to 171 deals.
This quarterly summary includes data on where venture capital investments and funding were made, the nature of transactions that took place as well as the geographic distribution of funding for the biotechnology and medical device sectors during the first quarter 2012.
To download the report, click here.
Mobile technology has long been viewed as an innovation with much potential to transform the healthcare industry and address long-standing issues. Yet there is little understanding of how to harness its power or develop business models that work.
Emerging mHealth: Paths for Growth, an Economist Intelligence Unit report commissioned by PwC examines the current state and potential of mHealth in developed and emerging markets, the ongoing barriers to its adoption and the implications for companies in the field.
Key insights include:
Download the report at www.pwc.com/mhealth.
The House Ways and Means Committee yesterday voted 23 to 11 to approve the "Protect Medical Innovation Act" (H.R. 436), a bill to repeal a medical device excise tax scheduled to be effective in 2013 under the 2010 health care law. The Ways and Means Committee also approved a bill providing for a $500 taxable cash-out exception from flexible spending account "use-it-or-lose-it" rules (H.R. 1004); a bill repealing a restriction on use of flexible spending accounts to purchase over-the-counter drugs (H.R. 5842); and a bill modifying health savings account rules (H.R. 5858). The full House is expected to vote on the four health care-related measures as early as next week.
To read more, click here.
In the face of business model challenges, declining R&D budgets, and expirations of blockbuster patents, the pharmaceuticals and life sciences industry is among several that may benefit from a proposed US “patent box” tax regime. A US patent box — deriving its name from a box on the corporate tax form — would reward companies for commercializing innovative products by taxing the profits on their sale at a reduced rate. Such a regime in the United States could substantially reduce what now ranks as the highest tax rate among the Organization for Economic Cooperation and Development (OECD) countries for intellectual property (IP) income.
Supporters of a US patent box regime suggest, among other things, that it would further competitiveness of US companies and encourage the development and retention of IP within US borders. As some countries have done, the scope of the patent box regime could be expanded beyond patents to encourage a broader array of innovation-based intellectual property.
To obtain additional information, click here.